Latest Information

Below you can access the latest press releases, financial reports, corporate governance documents and more. Please note that some documents may refer to Liminal BioSciences' previous name Prometic Life Sciences Inc.

  • LMNL Corporate Presentation

    LMNL Corporate Presentation

    Read PDF
  • LMNL presents new preclinical data on PBI-4050 and its effect on angio-proliferative pulmonary arterial hypertension

    LMNL presents new preclinical data on PBI-4050 and its effect on angio-proliferative pulmonary arterial hypertension

    LMNL to present two scientific posters with new preclinical data for PBI-4050 and the treatment of pulmonary arterial hypertension (“PAH”) at the American Heart Association conference.

    Read Article
  • Liminal BioSciences to present at the Jefferies 2019 London healthcare conference

    Liminal BioSciences to present at the Jefferies 2019 London healthcare conference

    Members of the management team will provide a business overview and update at the Jefferies 2019 London Healthcare Conference at 18:00 GMT on Wednesday, November 20, 2019 in London, UK.

    Read Article
  • Liminal BioSciences announces effectiveness of registration statement on form F-10 and filing of prospectus supplement

    Liminal BioSciences announces effectiveness of registration statement on form F-10 and filing of prospectus supplement

    LMNL announced today that its registration statement on Form F-10 (the “Registration Statement”), which was filed with the United States Securities and Exchange Commission (the “SEC”) on November 12

    Read Article
  • Press Releases

    Read More
  • Quarterly Report Q3 2019

    Quarterly Report Q3 2019

    Read PDF
  • Quarterly Report 2019 Q2

    Quarterly Report 2019 Q2

    Read PDF
  • Quarterly Report 2019 Q1

    Quarterly Report 2019 Q1

    Read PDF
  • Financial Reports

    Read Now
  • Nasdaq Statement of Corporate Governance Differences

    Nasdaq Statement of Corporate Governance Differences

    Read PDF
  • Board of Directors Charter 2019

    Board of Directors Charter 2019

    Read PDF
  • Code of Ethics and Business Conduct 2019

    Code of Ethics and Business Conduct 2019

    Read PDF
  • Position Description Lead Independent Director 2019

    Position Description Lead Independent Director 2019

    Read PDF
  • HR & Corporate Governance Committee Charter 2019

    HR & Corporate Governance Committee Charter 2019

    Read PDF
  • Corporate Governance

    Read More
  • Rare Disease: Alström Syndrome4:18

    Rare Disease: Alström Syndrome

    John and Kay Parkinson are the parents of two children who were diagnosed very late with the ultra-rare disease Alström Syndrome.

    Watch Video
  • LMNL Share Price

    View Now
  • Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency2:17

    Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency

    At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD).

    Watch Video
  • ×

    Get the updates before everyone else.

    First Name
    Last Name
    * By completing and submitting this form, you understand and agree that use of Liminal BioSciences' web site is subject to Liminal BioSciences Privacy Policy
    !
    Thank you!
    Error - something went wrong!
  • Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment1:41

    Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment

    Prometic Life Science's senior director details the promising efficacy PBI-4050 alone or in combination with nintedanib demonstrated for treatment of IPF.

    Watch Video
  • Interested in Investment Opportunities?

    Contact Us
  • loading
    Loading More...